{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:53:12Z","timestamp":1794804792856,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current cancer immunotherapies have made tremendous impacts but generally lack high response rates, especially in ovarian cancer. New therapies are needed to provide increased benefits. One understudied approach is to target the large population of immunosuppressive tumor-associated macrophages (TAMs). Using inducible transgenic mice, we recently reported that upregulating nuclear factor-kappaB (NF-\u03baB) signaling in TAMs promotes the M1, anti-tumor phenotype and limits ovarian cancer progression. We also developed a mannose-decorated polymeric nanoparticle system (MnNPs) to preferentially deliver siRNA payloads to M2, pro-tumor macrophages in vitro. In this study, we tested a translational strategy to repolarize ovarian TAMs via MnNPs loaded with siRNA targeting the inhibitor of NF-\u03baB alpha (I\u03baB\u03b1) using mouse models of ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated treatment with MnNPs loaded with I\u03baB\u03b1 siRNA (I\u03baB\u03b1-MnNPs) or scrambled siRNA in syngeneic ovarian cancer models. ID8 tumors in C57Bl\/6 mice were used to evaluate consecutive-day treatment of late-stage disease while TBR5 tumors in FVB mice were used to evaluate repetitive treatments in a faster-developing disease model. MnNPs were evaluated for biodistribution and therapeutic efficacy in both models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Stimulation of NF-\u03baB activity and repolarization to an M1 phenotype via I\u03baB\u03b1-MnNP treatment was confirmed using cultured luciferase-reporter macrophages. Delivery of MnNPs with fluorescent payloads (Cy5-MnNPs) to macrophages in the solid tumors and ascites was confirmed in both tumor models. A three consecutive-day treatment of I\u03baB\u03b1-MnNPs in the ID8 model validated a shift towards M1 macrophage polarization in vivo. A clear therapeutic effect was observed with biweekly treatments over 2-3\u2009weeks in the TBR5 model where significantly reduced tumor burden was accompanied by changes in immune cell composition, indicative of reduced immunosuppressive tumor microenvironment. No evidence of toxicity associated with MnNP treatment was observed in either model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In mouse models of ovarian cancer, MnNPs were preferentially associated with macrophages in ascites fluid and solid tumors. Evidence of macrophage repolarization, increased inflammatory cues, and reduced tumor burden in I\u03baB\u03b1-MnNP-treated mice indicate beneficial outcomes in models of established disease. We have provided evidence of a targeted, TAM-directed approach to increase anti-tumor immunity in ovarian cancer with strong translational potential for future clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-09612-2","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T19:04:06Z","timestamp":1651777446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Evan B.","family":"Glass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa A.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennady K.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Z.","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley I.","family":"Reinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetra H.","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Kimryn","family":"Rathmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Rathmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E.","family":"Yull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"9612_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol"},{"key":"9612_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet"},{"key":"9612_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","volume":"21","author":"J Sul","year":"2016","unstructured":"Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung Cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21:643\u201350.","journal-title":"Oncologist"},{"key":"9612_CR4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2.","journal-title":"Lancet Oncol"},{"key":"9612_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"9612_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"9612_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"9612_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"9612_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:1\u201318.","journal-title":"J Immunother Cancer"},{"key":"9612_CR10","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33:4015\u201322.","journal-title":"J Clin Oncol"},{"key":"9612_CR11","doi-asserted-by":"publisher","unstructured":"Matulonis UA, Shapira-Frommer R, Santin A, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study. Ann Oncol. 2019;30;1080\u201387. https:\/\/doi.org\/10.1093\/annonc\/mdz135.","DOI":"10.1093\/annonc\/mdz135"},{"key":"9612_CR12","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1200\/EDBK_280539","volume":"3","author":"LE Kandalaft","year":"2020","unstructured":"Kandalaft LE, Odunsi K, Coukos G. Immune therapy opportunities in ovarian Cancer. Am Soc Clin Oncol Educ B. 2020;3:e228\u201340.","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"9612_CR13","doi-asserted-by":"crossref","unstructured":"Siegel R, Miller K, Fuchs H, Jemal A. Erratum to \u201cCancer statistics, 2021\u201d. CA Cancer J Clin. 2021;71:359\u20139.","DOI":"10.3322\/caac.21654"},{"key":"9612_CR14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(13)62146-7.","journal-title":"Lancet"},{"key":"9612_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast","year":"2009","unstructured":"Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415\u201328.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"9612_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/cancers10090302","volume":"10","author":"ML Drakes","year":"2018","unstructured":"Drakes ML, Stiff PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel). 2018;10(9):302.","journal-title":"Cancers (Basel)"},{"key":"9612_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2014.00137","volume":"4","author":"EK Colvin","year":"2014","unstructured":"Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:1\u20136.","journal-title":"Front Oncol"},{"key":"9612_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:1\u201312.","journal-title":"Front Oncol"},{"key":"9612_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"9612_CR20","doi-asserted-by":"crossref","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. Isolation and characterization of tumor cells from the ascites of ovarian Cancer patients: molecular phenotype of Chemoresistant ovarian tumors. PLoS One. 2012;7.","DOI":"10.1371\/journal.pone.0046858"},{"key":"9612_CR21","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.3892\/or.2016.5136","volume":"36","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Wu X, Wu Y, Wang X. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep. 2016;36:3472\u20138.","journal-title":"Oncol Rep"},{"key":"9612_CR22","doi-asserted-by":"publisher","unstructured":"Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis. 2020;11. https:\/\/doi.org\/10.1038\/s41419-020-2438-8.","DOI":"10.1038\/s41419-020-2438-8"},{"key":"9612_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jconrel.2015.12.037","volume":"223","author":"F Piaggio","year":"2016","unstructured":"Piaggio F, Kondylis V, Pastorino F, Di Paolo D, Perri P, Cossu I, et al. A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. J Control Release. 2016;223:165\u201377. https:\/\/doi.org\/10.1016\/j.jconrel.2015.12.037.","journal-title":"J Control Release"},{"key":"9612_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/cas.12202","volume":"104","author":"Y Lin","year":"2013","unstructured":"Lin Y, Wei C, Liu Y, Qiu Y, Liu C, Guo F. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci. 2013;104:1217\u201325.","journal-title":"Cancer Sci"},{"issue":"1","key":"9612_CR25","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10(1):3974.","journal-title":"Nat Commun"},{"key":"9612_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01512","volume":"9","author":"SD Jayasingam","year":"2020","unstructured":"Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Ch\u2019ng ES. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human Cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2020;9:1\u20139.","journal-title":"Front Oncol"},{"key":"9612_CR27","doi-asserted-by":"publisher","first-page":"16756","DOI":"10.1021\/acsomega.9b01465","volume":"4","author":"EB Glass","year":"2019","unstructured":"Glass EB, Masjedi S, Dudzinski SO, Wilson AJ, Duvall CL, Yull FE, et al. Optimizing mannose \u201cclick\u201d conjugation to polymeric nanoparticles for targeted siRNA delivery to human and murine macrophages. ACS Omega. 2019;4:16756\u201367.","journal-title":"ACS Omega"},{"issue":"1","key":"9612_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12885-020-07450-8","volume":"20","author":"AA Hoover","year":"2020","unstructured":"Hoover AA, Hufnagel DH, Harris W, Bullock K, Glass EB, Liu E, et al. Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer. BMC Cancer. 2020;20(1):970.","journal-title":"BMC Cancer"},{"key":"9612_CR29","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2147\/IJN.S93483","volume":"11","author":"RA Ortega","year":"2016","unstructured":"Ortega RA, Barham W, Sharman K, Tikhomirov O, Giorgio TD, Yull FE. Manipulating the NF-kB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions. Int J Nanomedicine. 2016;11:2163\u201377.","journal-title":"Int J Nanomedicine"},{"key":"9612_CR30","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1021\/acsnano.7b01110","volume":"11","author":"MA Jackson","year":"2017","unstructured":"Jackson MA, Werfel TA, Curvino EJ, Yu F, Kavanaugh TE, Sarett SM, et al. Zwitterionic Nanocarrier surface chemistry improves siRNA tumor delivery and silencing activity relative to polyethylene glycol. ACS Nano. 2017;11:5680\u201396.","journal-title":"ACS Nano"},{"key":"9612_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2020.120528","volume":"268","author":"MA Jackson","year":"2021","unstructured":"Jackson MA, Patel SS, Yu F, Cottam MA, Glass EB, Hoogenboezem EN, et al. Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers. Biomaterials. 2021;268:1\u201312. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120528.","journal-title":"Biomaterials"},{"key":"9612_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/mt.2011.294","volume":"20","author":"RL Kanasty","year":"2012","unstructured":"Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20:513\u201324. https:\/\/doi.org\/10.1038\/mt.2011.294.","journal-title":"Mol Ther"},{"key":"9612_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/nat.2017.0715","volume":"28","author":"RR Nikam","year":"2018","unstructured":"Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther. 2018;28:209\u201324.","journal-title":"Nucleic Acid Ther"},{"key":"9612_CR34","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1111\/j.1742-4658.2010.07904.x","volume":"277","author":"MS Shim","year":"2010","unstructured":"Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010;277:4814\u201327.","journal-title":"FEBS J"},{"key":"9612_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13143422","volume":"13","author":"JM Debacker","year":"2021","unstructured":"Debacker JM, Gondry O, Lahoutte T, Keyaerts M, Huvenne W. The prognostic value of CD206 in solid malignancies: a systematic review and Meta-analysis. Cancers (Basel). 2021;13:1\u201316.","journal-title":"Cancers (Basel)"},{"key":"9612_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/mp300434e","volume":"10","author":"SS Yu","year":"2013","unstructured":"Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, et al. Macrophage-specific RNA interference targeting via &quot;click&quot;, mannosylated polymeric micelles. Mol Pharm. 2013;10:975\u201387. https:\/\/doi.org\/10.1021\/mp300434e.","journal-title":"Mol Pharm"},{"key":"9612_CR37","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12:967\u201377. https:\/\/doi.org\/10.1038\/nmat3765.","journal-title":"Nat Mater"},{"key":"9612_CR38","first-page":"51","volume":"9","author":"N Oh","year":"2014","unstructured":"Oh N, Park J-H. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine. 2014;9:51\u201363.","journal-title":"Int J Nanomedicine"},{"key":"9612_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.607945","volume":"11","author":"MV Baranov","year":"2021","unstructured":"Baranov MV, Kumar M, Sacanna S, Thutupalli S, van den Bogaart G. Modulation of immune responses by particle size and shape. Front Immunol. 2021;11:1\u201323.","journal-title":"Front Immunol"},{"key":"9612_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1039\/C4NR03962A","volume":"7","author":"RA Ortega","year":"2015","unstructured":"Ortega RA, Barham WJ, Kumar B, Tikhomirov O, McFadden ID, Yull FE, et al. Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale. 2015;7:500\u201310.","journal-title":"Nanoscale"},{"key":"9612_CR41","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1021\/nn403325f","volume":"7","author":"CE Nelson","year":"2013","unstructured":"Nelson CE, Kintzing JR, Hanna A, Shannon JM, Gupta MK, Duvall CL. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano. 2013;7:8870\u201380.","journal-title":"ACS Nano"},{"key":"9612_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-7-19","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:1\u201316.","journal-title":"J Ovarian Res"},{"key":"9612_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-63276-1","volume":"10","author":"A Macci\u00f2","year":"2020","unstructured":"Macci\u00f2 A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. Sci Rep. 2020;10:1\u20138.","journal-title":"Sci Rep"},{"key":"9612_CR44","first-page":"1136","volume":"13","author":"KV Kilchrist","year":"2019","unstructured":"Kilchrist KV, Dimobi SC, Jackson MA, Evans BC, Werfel TA, Dailing EA, et al. Gal8 visualization of endosome disruption predicts carrier-mediated biologic drug intracellular bioavailability. ACS Nano. 2019;13:1136\u201352.","journal-title":"ACS Nano"},{"key":"9612_CR45","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.18632\/oncotarget.3860","volume":"6","author":"AJ Wilson","year":"2015","unstructured":"Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, et al. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015;6:21353\u201368.","journal-title":"Oncotarget"},{"key":"9612_CR46","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.1073\/pnas.0502256102","volume":"102","author":"D Xing","year":"2005","unstructured":"Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A. 2005;102:6936\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9612_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-015-0060-6","volume":"3","author":"JB Liao","year":"2015","unstructured":"Liao JB, Ovenell KJ, Curtis EEM, Cecil DL, Koehnlein MR, Rastetter LR, et al. Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. J Immunother Cancer. 2015;3:1\u20139.","journal-title":"J Immunother Cancer"},{"key":"9612_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-6-63","volume":"6","author":"AJ Wilson","year":"2013","unstructured":"Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee H, et al. Tracking NF- \u03baB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res. 2013;6:1\u201311. https:\/\/doi.org\/10.1186\/1757-2215-6-63.","journal-title":"J Ovarian Res"},{"key":"9612_CR49","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1158\/0008-5472.CAN-06-1495","volume":"66","author":"D Xing","year":"2006","unstructured":"Xing D, Orsulic S. A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma. Cancer Res. 2006;66:8949\u201353.","journal-title":"Cancer Res"},{"key":"9612_CR50","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20080108","volume":"205","author":"T Hagemann","year":"2008","unstructured":"Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al. \u201cRe-educating\u201d tumor-associated macrophages by targeting NF-\u03baB. J Exp Med. 2008;205:1261\u20138.","journal-title":"J Exp Med"},{"key":"9612_CR51","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.4049\/jimmunol.176.8.4995","volume":"176","author":"MB Everhart","year":"2006","unstructured":"Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, et al. Duration and intensity of NF-\u03baB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006;176:4995\u20135005.","journal-title":"J Immunol"},{"key":"9612_CR52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/1541-7786.MCR-07-0309","volume":"6","author":"GT Stathopoulos","year":"2008","unstructured":"Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-\u03baB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008;6:364\u201371.","journal-title":"Mol Cancer Res"},{"key":"9612_CR53","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.4049\/jimmunol.1201809","volume":"190","author":"W Han","year":"2013","unstructured":"Han W, Li H, Cai J, Gleaves LA, Polosukhin VV, Segal BH, et al. NADPH oxidase limits lipopolysaccharide-induced lung inflammation and injury in mice through reduction-oxidation regulation of NF-\u03baB activity. J Immunol. 2013;190:4786\u201394.","journal-title":"J Immunol"},{"key":"9612_CR54","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/aps.2017.124","volume":"38","author":"M Tariq","year":"2017","unstructured":"Tariq M, Zhang JQ, Liang GK, He QJ, Ding L, Yang B. Gefitinib inhibits M2-like polarization of tumorassociated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017;38:1501\u201311. https:\/\/doi.org\/10.1038\/aps.2017.124.","journal-title":"Acta Pharmacol Sin"},{"key":"9612_CR55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593:282\u20138. https:\/\/doi.org\/10.1038\/s41586-021-03442-1.","journal-title":"Nature"},{"key":"9612_CR56","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"9612_CR57","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1091\/mbc.e08-02-0139","volume":"19","author":"AJ Wilson","year":"2008","unstructured":"Wilson AJ, Byun D-S, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of Colon Cancer cells via repression of p21. Mol Biol Cell. 2008;19:4062\u201375.","journal-title":"Mol Biol Cell"},{"key":"9612_CR58","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.","journal-title":"Signal Transduct Target Ther"},{"key":"9612_CR59","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fimmu.2019.00705","volume":"10","author":"MG Dorrington","year":"2019","unstructured":"Dorrington MG, Fraser IDC. NF-\u03baB signaling in macrophages: dynamics, crosstalk, and signal integration. Front Immunol. 2019;10:705.","journal-title":"Front Immunol"},{"key":"9612_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-015-0177-8","volume":"8","author":"AJ Wilson","year":"2015","unstructured":"Wilson AJ, Saskowski J, Barham W, Yull F, Khabele D. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. J Ovarian Res. 2015;8:1\u201310. https:\/\/doi.org\/10.1186\/s13048-015-0177-8.","journal-title":"J Ovarian Res"},{"key":"9612_CR61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tranon.2018.08.020","volume":"12","author":"I Wilkinson-ryan","year":"2019","unstructured":"Wilkinson-ryan I, Pham MM, Sergent P, Tafe LJ, Berwin BL. A syngeneic mouse model of epithelial ovarian Cancer port site metastases. Transl Oncol. 2019;12:62\u20138. https:\/\/doi.org\/10.1016\/j.tranon.2018.08.020.","journal-title":"Transl Oncol"},{"key":"9612_CR62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/cyto.a.22012","volume":"81","author":"S Rose","year":"2012","unstructured":"Rose S, Misharin A, Perlman H. A novel Ly6C\/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytom A. 2012;81:343\u201350.","journal-title":"Cytom A"},{"key":"9612_CR63","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.2147\/IJN.S207589","volume":"14","author":"J Ye","year":"2019","unstructured":"Ye J, Yang Y, Dong W, Gao Y, Meng Y, Wang H, et al. Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages. Int J Nanomedicine. 2019;14:3203\u201320.","journal-title":"Int J Nanomedicine"},{"key":"9612_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aax6337","volume":"12","author":"JM Jaynes","year":"2020","unstructured":"Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020;12:1\u201320.","journal-title":"Sci Transl Med"},{"key":"9612_CR65","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2217\/nnm.15.86","volume":"10","author":"E Huynh","year":"2015","unstructured":"Huynh E, Zheng G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine. 2015;10:1993\u20135 www.futuremedicine.com.","journal-title":"Nanomedicine"},{"key":"9612_CR66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","volume":"244","author":"F Danhier","year":"2016","unstructured":"Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108\u201321. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.015.","journal-title":"J Control Release"},{"key":"9612_CR67","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","volume":"19","author":"S Sindhwani","year":"2020","unstructured":"Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19:566\u201375. https:\/\/doi.org\/10.1038\/s41563-019-0566-2.","journal-title":"Nat Mater"},{"key":"9612_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","volume":"58","author":"A Macci\u00f2","year":"2012","unstructured":"Macci\u00f2 A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58:133\u201347.","journal-title":"Cytokine"},{"key":"9612_CR69","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.2147\/CMAR.S179189","volume":"10","author":"L Browning","year":"2018","unstructured":"Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685\u201393.","journal-title":"Cancer Manag Res"},{"key":"9612_CR70","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0729-3","volume":"563","author":"PS Gonzalez","year":"2018","unstructured":"Gonzalez PS, O\u2019Prey J, Cardaci S, Barthet VJA, Ichi SJ, Beaumatin F, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563:719\u201323. https:\/\/doi.org\/10.1038\/s41586-018-0729-3.","journal-title":"Nature"},{"key":"9612_CR71","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ncomms1239","volume":"2","author":"OAW Haabeth","year":"2011","unstructured":"Haabeth OAW, Lorvik KB, Hammarstr\u00f6m C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09612-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T06:05:06Z","timestamp":1668319506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9612"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09612-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Vanderbilt University Institutional Animal Care and Use Committee and were conducted in accordance with American Association for Laboratory Animal Science (AALAS) and ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"497"}}